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self-report as a proxy for in-person follow up in a cellulitis
treatment trial comparing cephalexin alone with cephalexin-plus-
trimethoprim/sulfamethoxazole. Our results demonstrate poor
agreement between these two methods of outcome determination
and have implications for future cellulitis clinical trial design and
clinical management.
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E-mail: vnambudiri@partners.orgSkin and soft-tissue infections are common, diagnosed at over
3% of all US emergency department visits and 1% of US phy-
sicians’ ofﬁce visits [1,2]. These infections are also common
targets of randomized controlled trials (RCTs) [3]. Two new
agents—dalbavancin and tedizolid—were approved in 2014 for
treating acute bacterial skin infections after successful large-
scale RCTs [4,5].Microbiol Infect 2015; 21: 676.e5–676.e7
nical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infect
p://dx.doi.org/10.1016/j.cmi.2015.03.008Cellulitis is particularly challenging for researchers and cli-
nicians because most cases do not harbour cultivable micro-
organisms, and the deﬁnition and timing of cure are debatable
[3]. In 2013, the US Food and Drug Administration released
guidelines regarding cellulitis drug development trial design [6].
These guidelines recommend four study visits: entry, on-
therapy, end-of-therapy and after-therapy visits. We recently
published an RCT of antimicrobial agents for cellulitis [7]. In
planning the trial, we struggled with the question of whether
in-person follow up was needed: could patients self-report
treatment outcome by telephone? Telephone follow up has
been previously employed for cure assessment in cellulitis [8,9].
Uncertain of telephone-based assessment validity, we obtained
outcomes both in-person and by telephone, with plans to
prospectively analyse telephone report as a proxy for in-person
follow up, and report the results herein.
Our RCT enrolled emergency department patients treated
as outpatients for uncomplicated cellulitis, with cephalexin-plus-
placebo versus cephalexin-plus-trimethoprim/sulfamethoxazole
[7]. Participants presented to one of three emergency de-
partments, were diagnosed with cellulitis by an emergency
physician (study day 0), and continued treatment until 3 days
after they believed the cellulitis had been cured for a minimum
of 7 days to a maximum of 14 days.
Treatment efﬁcacy was assessed at in-person follow up
encounters on day 12 ± 2, and by telephone interviews 1 day
prior to this, referred to as ‘day 12’ and ‘day 11’, respectively.
For the trial’s main outcome, we included treatment failures
that occurred before or after these pre-planned follow-up
visits. Participants evaluated by telephone on day 11 and in-
person on day 12 were those who had not already been
designated treatment failures, comprising our study sample in
this analysis. Telephone follow up was performed by research
technicians, trained by the primary investigator (D.J.P.), using a
standardized evaluation script with all responses reviewed by an
emergency physician. In-person follow up was performed by an
emergency physician in the same hospital at which the patient
had been diagnosed with cellulitis using a structured evaluation
script.
We compared telephone follow up to in-person follow up,
quantifying agreement using κ scores. For in-person cure
determinations (criterion standard), cure was deﬁned as
physician-assessed resolution of all symptoms other than slight
residual erythema or swelling not worse than at enrolment. For
telephone cure determinations, we used the same criteria as
reported by study subjects. We designated participants treat-
ment failures if they reported a subjective sense that the
infection was not cured, or reported uncertainty about this. On
day 30, we telephoned participants, reviewed medical records,ious Diseases. Published by Elsevier Ltd. All rights reserved
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ments for analysis [7]. We performed all analyses using SAS 9.2
(SAS Institute, Cary, NC, USA). The study was approved by the
institutional review boards of each participating hospital; the
research plan described here was planned prospectively and
described in the original registration, ClinicalTrials.gov
NCT00676130.
The original intent-to-treat analysis included 146 subjects
who completed the study protocol [7]. The median age of
participants was 29 years (range 3–74 years; interquartile range
23–43), 60% of participants were Caucasian and 16% were
Black. Of the participants, 21% were healthcare workers, 34%
had a history of previous skin infections, and 39% had been on
antibiotics at least once in the preceding year. Twenty partici-
pants lacked data for both day 11 telephone follow up and day
12 in-person follow up because they had already failed treat-
ment (n = 16) or simply did not follow up (n = 4). Of the
remaining 126 (86% of 146), 12 (10%) had in-person visits but
no telephone follow up, and 15 (12%) had telephone follow up
but no in-person visit. Hence, 99 (79% of 126) completed both
telephone and in-person assessments and were included for
analysis.
Our main results are shown in Fig. 1. The κ statistic was used
for analysis to quantify intermodality cure assessment
disagreement. There was poor agreement between telephone
and in-person ascertainments of cure, with a κ score of 0.16. Of
ﬁve cases deemed treatment failures based on in-person follow
up, two (40%) were deemed by telephone assessment to have
been cured. Of 94 cases deemed cured based on in-person
follow up, 18 (11%) were deemed failures by telephone.
In this pre-planned secondary analysis assessing telephone
interview versus in-person assessment in determination of
cellulitis cure, we had hoped to ﬁnd that telephone interview
would be an adequate proxy, making cellulitis RCTs less
expensive and easier for participants. Instead, we found tele-
phone assessment to be a poor proxy for in-person assessment
of cure in cellulitis trials. Telephone follow-up assessment has
been employed in cellulitis in several recently completed trials
or as part of ongoing protocols investigating antibiotic efﬁcacyFIG. 1. Self-report by telephone as a
proxy for in-person determination of
cure in a cellulitis drug trial. There
were 146 patients in the original
intent-to-treat analysis. Included in
the present analysis are the 99 (68%)
who had not already failed therapy,
and who participated in both tele-
phone and in-person follow up.
Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and In[8,9]. Telephone follow up presents several theoretical advan-
tages, including lowering patients’ costs of travel to clinical sites,
decreasing physician time required for follow-up visits by
eliminating waiting time between successive patient encounters,
and freeing up clinical space for urgent or acute clinical visits.
Given the importance of patient-reported outcomes, empow-
ering patients to determine treatment success is an attractive
goal. However, since our ﬁndings suggest poor agreement with
in-person follow-up assessment, cellulitis trials with efﬁcacy
based solely on telephone data should be interpreted
cautiously.
There are several important caveats to our ﬁnding. The
importance of cure assessment at any single time point is
dubious. The US Food and Drug Administration has emphasized
early treatment response assessment as an indicator of efﬁcacy;
however, cellulitis is indolent, and the inﬂammation and edema
often take time to clear. Improvement at 72 h due to adjunctive
measures (e.g. compression and elevation) may not predict
ultimate cure. Such early follow-up visits probably capture
dramatic cure events, but are probably not valid measures of
failure events. The ultimate determination of cure or failure
depends on global assessments of the overall course of illness.
An important caveat to our ﬁnding is that perhaps neither
patients nor clinicians are sure when cellulitis is cured. We are
presently assembling a meta-analysis of medication trials for
cellulitis, and preliminary data suggest that treatment failure
rates have hovered around 20% for decades regardless of study
medications. Moreover, cellulitis lesions yield cultivable organ-
isms in <30% of cases and positive blood cultures in <4% of
cases [10]. These observations suggest that many cases of
cellulitis may not be straightforward Gram-positive bacterial
infections as we often believe them to be.
Finally, this pre-planned secondary analysis is limited by its
size. However, as our ﬁndings demonstrate non-equivalence,
this concern is mitigated, offering convincing insight that tele-
phone follow up is a poor surrogate for in-person evaluation
for at least some cases. It bears mention that video follow up is
a promising option that we did not study. We speculate that
follow up incorporating imaging would lessen the differencefectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 676.e5–676.e7
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